New hope exists in treating inherited disease by suppressing DNA mutations

Apr 26, 2010

Genetic mutation can disrupt the way human cells make proteins, which in turn leads to inherited disease. David Bedwell, a professor in the University of Alabama at Birmingham (UAB) Department of Microbiology, says scientists are closer than ever to producing drugs that fix this disrupted-protein pathway and drastically improving treatment of genetic disease.

Bedwell is a renowned researcher on a select group of genetic alterations called nonsense mutations - DNA alterations that can lead to nonfunctional or missing proteins. He will present a lecture today at the Experimental Biology 2010 conference.

His talk, "Pharmacological suppression of nonsense mutations to treat ," examines the promise of Bedwell's groundbreaking research on the ataluren (formerly called PTC124) that may help to treat some cystic fibrosis patients. Ataluren also holds promise in treating more than 2,400 different genetic disorders caused by nonsense mutations.

"When treating a genetic disease with suppression therapy, the key consideration is the fraction of the missing protein that must be restored to yield a therapeutic benefit," Bedwell says. "It comes down to the threshold of protein rescue needed. For some diseases, it might be one percent of the normal amount of protein that must be restored, and for other diseases, you may need 50 percent of protein restored."

In Bedwell's most well-known study, ataluren restored up to 29 percent of normal protein function in mice with cystic fibrosis. Another researcher not affiliated with UAB has reported ataluren restored up to 25 percent of the missing or abnormal in mice with Duchenne muscular dystrophy.

An estimated one-third of gene defects responsible for human disease are thought to come from nonsense mutations. In the case of cystic fibrosis, the absence of a certain protein leads to an imbalance of salt and water in the linings of the lungs and other membranes. The UAB study showed that ataluren allowed the protein to be made in mouse cells where it was previously absent, and it helped the body's regulatory system to restore salt and water balance in the membrane.

Bedwell says the true promise of drugs that suppress nonsense mutations is their selectiveness, meaning the drugs work well to suppress disease-causing mutations while generally sparing healthy genes.

Ataluren is now being tested in humans for its effectiveness in treating Duchenne/Becker muscular dystrophy, , hemophilia A, hemophilia B and other conditions. The agent works in an oral form.

Explore further: Serotonin neuron subtypes: New insights could inform SIDS understanding, depression treatment

add to favorites email to friend print save as pdf

Related Stories

Drug fights cystic fibrosis

Feb 05, 2008

An experimental drug that has proven effective in treating muscular dystrophy also works for cystic fibrosis, according to researchers at the University of Alabama at Birmingham (UAB).

New gene linked to muscular dystrophy

Aug 10, 2009

Muscular dystrophy, a group of inherited diseases characterized by progressive skeletal muscle weakness, can be caused by mutations in any one of a number of genes. Another gene can now be added to this list, as Yukiko Hayashi ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.